Cellectis S.A. (NASDAQ:CLLS – Get Free Report) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.03 and traded as high as $3.41. Cellectis shares last traded at $3.24, with a volume of 4,833 shares.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on CLLS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays assumed coverage on Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.
Check Out Our Latest Analysis on Cellectis
Cellectis Price Performance
Cellectis (NASDAQ:CLLS – Get Free Report) last released its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.
Institutional Investors Weigh In On Cellectis
Institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC bought a new position in Cellectis in the fourth quarter worth about $34,000. Lido Advisors LLC bought a new position in shares of Cellectis during the first quarter valued at approximately $32,000. Millennium Management LLC grew its holdings in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Cellectis during the 3rd quarter worth approximately $72,000. Finally, Acadian Asset Management LLC raised its position in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Institutional investors own 63.90% of the company’s stock.
About Cellectis
Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.
The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.
See Also
- Five stocks we like better than Cellectis
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
